Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke(University of Genoa), John Sidney(La Jolla Institute for Immunology), Nils Methot(La Jolla Institute for Immunology), Esther Dawen Yu(La Jolla Institute for Immunology), Yun Zhang(J. Craig Venter Institute), Jennifer M. Dan(University of California, San Diego), Benjamin Goodwin(La Jolla Institute for Immunology), Paul Rubiro(La Jolla Institute for Immunology), Aaron Sutherland(La Jolla Institute for Immunology), Eric Wang(La Jolla Institute for Immunology), April Frazier(La Jolla Institute for Immunology), Sydney I. Ramirez(University of California, San Diego), Stephen A. Rawlings(University of California, San Diego), Davey M. Smith(University of California, San Diego), Ricardo da Silva Antunes(La Jolla Institute for Immunology), Bjoern Peters(La Jolla Institute for Immunology), Richard H. Scheuermann(University of California, San Diego), Daniela Weiskopf(La Jolla Institute for Immunology), Shane Crotty(University of California, San Diego), Alba Grifoni(La Jolla Institute for Immunology), Alessandro Sette(University of California, San Diego)
Cell Reports Medicine
July 1, 2021
10.1016/j.xcrm.2021.100355
Cited by 675Open Access
Full Text

Abstract

T cell epitopes, respectively, are affected by mutations in the various VOCs. Thus, the SARS-CoV-2 variants analyzed here do not significantly disrupt the total SARS-CoV-2 T cell reactivity; however, the decreases observed highlight the importance for active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution.

Related Papers

No related papers found

Powered by citation graph analysis